

Meeting Agenda

Division	Iowa Medicaid Quality Improvement Organization (QIO)		
Meeting Title	Clinical Advisory Committee (CAC)		
CAC Chair	Bill Jagiello, DO		
Facilitator	Julie Riegel		
Date	April 17, 2026	TIME	1:00pm - 4:00pm
Location	Virtual: Via Zoom: https://telligen.zoom.us/join/92nF2rIA In-Person: Lucas Building Capitol Complex, 321 E 12 th St, Des Moines, Conference Room L221		

Meeting Objectives

The purpose of the CAC is to increase the efficiency, quality, and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness, and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.

The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions to the Department of Health and Human Services (HHS) for the Iowa Medicaid program.

HIPAA Reminder: As a reminder to all members of the public who are presenting during the CAC meeting: Do not provide any personal health information (PHI) regarding a member covered by Iowa Medicaid Insurance that would constitute a violation of Federal HIPAA standards.

Meeting Participants

Iowa Medicaid	☒ Michael Line, MD, HHS Chief Medical Officer ☐ Rebecca Curtiss, HHS Deputy Director of Operations ☐ Jenny Erdman, HHS Quality, Innovation & Medical Policy Bureau Chief ☐ Andrea Maher, HHS LTSS Bureau Chief ☒ Tami Lichtenberg, QIO Director ☒ Bill Jagiello, DO, QIO ☒ Else Umbreit, PharmD, QIO ☒ Carrie Ortega, Sr. Operations Manager, QIO
Committee Members	☒ Dana Danley, MD, Family Practice ☒ Diana Smith, ARNP-Family Practice ☒ Chitra Reddy, MD, Endocrinology ☒ Geetanjali Sahu, MD, Child and Adolescent Psychiatrist ☒ Wendy Sanders, ARNP-Family Practice ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics ☒ Kelli Roenfan, DO, Family Medicine, OB/Gyn ☐ Kaaren Olesen, DO, OB/Gyn



Managed Care
Organizations

- ☐ Dr. Paul Mulhausen, Iowa Total Care
- ☐ Dr. Timothy Gutshall, Molina Healthcare of Iowa
- ☒ Dr. Jason Kessler, Wellpoint
- ☐ Dr. James Elliot, Managed Care of North America
- ☐ Dr. Jeff Chaffin, Delta Dental of Iowa

Agenda Topic

Public Comment Period

- A maximum of 5 minutes will be allotted to each public guest who has submitted a completed [Conflict of Interest Disclosure](#). Submissions must be received no later than one week prior to the meeting date.
- To be respectful of the meeting time if you find your topic will exceed the maximum 5-minute allotment we welcome you to submit your detailed information to CAC@hhs.iowa.gov prior to and/or post meeting.

Announcements

- Introduction: Dr. Michael Line, Chief Medical Officer, Iowa Medicaid.

• Approval of January 16, 2026 Meeting Minutes

New Business

Consent Agenda

Durable Medical Equipment (6):

1. Augmentative Communication Systems
2. Back-Up Ventilator
3. Gait Trainer/Stander
4. Power Seat Elevation for Power Wheelchairs
5. Safety Beds
6. Shower/Commode Chair

Home Health (2):

7. Personal Care Services for Children
8. Private Duty Nursing for Children

Lab (1):

9. Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer

Level of Care (3):

10. Nursing Facility Level of Care
11. Pediatric Skilled Nursing Facility Level of Care
12. Skilled Level of Care

Surgical Procedures (3):

13. Bariatric Surgery
14. Cochlear Implant Repair and Replacement
15. Pancreas Transplant

Waiver Prior Authorization (2):

16. Consumer Directed Attendant Care
17. Prevocational Services

Physician Administered Medications (21):

18. Botulinum Toxins
19. Briumvi (ublituximab-xiiy)
20. Crysvita (burosumab-twza)
21. Elaprase (idursulfase)
22. Elfabrio (pegunigalsidase alfa-iwxj)
23. Enjaymo (sutimlimab-jome)
24. Jelmyto (mitomycin gel)
25. Korsuva (difelikefalin)
26. Krystexxa (pegloticase)
27. Lamzedo (velmanase alfa-tycv)
28. Luxturna (voretigene neparvovec-rzyl)
29. Natalizumab Agents (Tysabri, Tyruko)
30. Nexvazyme (avalglucosidase alfa-ngpt)
31. Qalsody (tofersen)
32. Radicava (edaravone)
33. Rystiggo (rozanolixizumab-noli)
34. Spravato (esketamine nasal spray)
35. Tepezza (teprotumumab-trbw)
36. Tzield (teplizumab-mzwv)
37. Veopoz (pozelimab-bbfg)
38. Xenpozyme (olipudase alfa-rpcp)

Criteria Review

Physician Administered Medications - Review (4):

1. Amvuttra (vutrisiran)
2. Elevidys (delandistrogene moxeparvovec-rokl)
 - Stephanie Kennedy, PharmD, MBA, Sarepta.
3. Keytruda (pembrolizumab)
4. Kymriah (tisagenlecleucel)

Upcoming Meetings

- Friday, July 17, 2026
 - Virtual Meeting Link: https://telligen.zoom.us/meeting/register/Zy-MrAZjRc-j_qcidI_J6w
- Friday, October 16, 2026
 - Virtual Meeting Link: <https://telligen.zoom.us/meeting/register/8zkFKattQXiLe05PVFIP3A>

Adjournment

Additional Information

- **Iowa Medicaid CAC contact:** CAC@hhs.iowa.gov
- **Iowa Medicaid CAC webpage:** <https://hhs.iowa.gov/about/advisory-groups/clinical-advisory-committee-cac>
- **Iowa Medicaid Fee Schedules webpage:** <https://hhs.iowa.gov/programs/welcome-iowa-medicaid/policies-rules-and-regulations/covered-services-rates-and-payments/fee-schedules>
- **Guests wanting to speak during the public comment period must complete a [CAC Disclosure Form](#) and email it to CAC@hhs.iowa.gov.** Submissions must be received no later than one week prior to the meeting date.

Meeting Minutes (Q2 2026)

Opening: Julie Riegel, Iowa Medicaid QIO, welcomed everyone to the quarterly Iowa Medicaid Clinical Advisory Committee (CAC) Meeting for 2026, and provided an overview of the house rules.

Verbal Roll Call of the Committee Members: Quorum was confirmed with 7 of 8 members.

Introduction: Julie introduced Committee Chairman, Dr. Jagiello, who is the Medical Director for Iowa Medicaid, QIO. Julie presented the Meeting Objectives and the instructions for the Public Comment period presentations, with the use of a visible timer for each Public Guest Speaker and allotment of 5 minutes to present.

Announcements: Dr. Jagiello introduced Chief Medical Officer, Dr. Michael Line, who spoke to the committee about himself and his background and position within Iowa Medicaid.

Approval of January 17, 2026, Minutes: Dr. Jagiello opened the vote to approve the minutes with no requests for any changes or corrections from the Committee.

Dr. Jagiello asked for motion to approve from the Committee.

- First motion to approve by Dr. Geetanjali Sahu
- Second motion to approve by Dawn Schwartz

Committee Member by roll call vote for approval:

- ☐ Dr. Dana Danley-Family Practice (abstained from voting absent January meeting)
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfan, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

Consent Agenda:

Julie Riegel provided the purpose of the Consent Agenda and explained the procedure for archiving criteria. Archival of criteria means the prior authorization requirements for the test or procedures are not going away, rather the criteria are being replaced by MCG Guidelines.

Dr. Jagiello asked the committee if there were any comments or questions about an item on the consent agenda, adding that a committee member may, at their request, take an item off the consent agenda and open it up for discussion. With no comments or questions heard, Dr. Jagiello asked for a motion to approve the consent agenda as presented.

Dr. Jagiello asked for motion to approve from the Committee.

- First motion to approve by Dr. Chitra Reddy
- Second motion to approve Diana Smith

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley-Family Practice
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

Criteria Review:

After the vote, Dr. Jagiello stated criteria for review consist of Physician Assisted Medications and Dr. Umbreit with the Iowa Medicaid Quality Improvement Organization would present.

Dr Umbreit announced that there were 4 medications on the Criteria Review to review.

1. Amvuttra (vutrisiran)

Dr. Umbreit presented the annual review. There is a new indication for treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults. Approved by the U.S. Food and Drug Administration (FDA) on 03/20/2025.

Dr. Jagiello thanked Dr. Umbreit and asked the committee if they had any questions or comments about the revised policy or criteria.

Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Dawn Schwartz
- Second motion to approve Dr. Dana Danley

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley-Family Practice
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

2. Elevidys (delandistrogene moxeparvovec-rokl)

Dr. Umbreit presented the annual review for Elevidys. Elevidys is a gene therapy for Duchenne muscular dystrophy in ambulatory patients who are at least 4 years of age.

On 11/14/2025, the Food and Drug Administration (FDA) modified the indication to no longer include use in non-ambulatory patients. Added requirement for liver monitoring into the criteria (based on information in boxed warning and monitoring recommendations).

Dr. Stephanie Kennedy spoke to the committee for allowing patients who need Elevidys to have access to this.

Dr. Jagiello thanked Dr. Umbreit and Dr. Kennedy and asked the committee if they had any questions or comments about the revised criteria.

Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Dr. Dana Danley
- Second motion to approve Wendy Sanders

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley-Family Practice
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

3. Keytruda (pembrolizumab)

Dr. Umbreit presented several updates in the annual review for Keytruda.

- For new FDA-approved indications: updated Appendix A with dosing and Coding & Product Information with ICD-10 codes.
- Added Patient Selection information to Overview section (e.g., biomarkers used in patient selection process).
- 06/17/2024: FDA approved new indication (17a) - in combination with carboplatin and paclitaxel, followed by Keytruda® as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. Criteria added.
- 09/17/2024: FDA approved new indication (3a) – in combination with pemetrexed

and platinum chemotherapy, as first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma. Criteria added.

- 03/19/2025 (FDA): Conversion of the gastric cancer indication in HER2-positive gastric or GEJ adenocarcinoma in adults (10a) from accelerated approval to traditional approval.
- 05/22/2025: FDA label change – modification to gastric cancer (10b) and esophageal cancer (11a) indications to include language “whose tumors express PD-L1 (CPS $\geq$ 1).” Updated criteria to mirror indication.
- 06/03/2025: FDA label change – modification to cervical cancer indication (12a) to “locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs.” Updates and additions made to criteria. d.
- 06/12/2025: FDA approved new indication (4a) – for the treatment of adult patients with resectable locally HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) $>$ 1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. Updated criteria to mirror indication.
- 07/24/2025 (FDA): Conversion of the previous accelerated approval to traditional approval for the 400 mg every 6-week dosing regimen in adult patients with classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma (removes indication 1.21 from prescribing information). Updated criteria to remove from indication list.
- 11/21/2025: FDA approved new indication (7c) – in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. Criteria added.
- 02/10/2026: FDA approved new indication (21) – in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS $\geq$ 1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.” Criteria added.

Dr. Jagiello thanked Dr. Umbreit and asked the committee if they had any questions or comments about the revised criteria.

Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Dr. Dana Danley
- Second motion to approve Dr. Geetanjali Sahu

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley-Family Practice
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

4. Kymriah (tisagenlecleucel)

Dr Umbreit presented the annual review for Kymriah.

- Updated boxed warning to reflect removal of REMS requirement and added post-infusion monitoring requirements in a separate table.
- Guidelines: reviewed and updated NCCN Guidelines.
- Removed criteria requirement for administration at a REMS facility.

Dr. Jagiello asked for a motion and a second to approve the criteria revision.

- First motion to approve by Dr. Dana Danley
- Second motion to approve Wendy Sanders

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley-Family Practice
- ☒ Diana Smith, ARNP-Family Practice
- ☒ Dr. Chitra Reddy-Endocrinology
- ☒ Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP-Family Practice
- ☒ Dawn Schwartz, ARNP- Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☐ Dr. Kaaren Olesen, DO OB/Gyn

Julie Riegel thanked everyone for joining and welcomed everyone to join the upcoming Quarter 3 CAC meeting on July 17, 2026.

Dr. Jagiello asked if there were any questions, hearing none asked for a motion to adjourn.

- First motion to adjourn by Dawn Schwartz
- Second motion to adjourn by Dr. Chitra Reddy